Share this article
Share this article
TAIPEI, Taiwan, Jan. 17, 2021 /PRNewswire/ Health and Biotech company MedFluid has developed the fastest, first-in-class antimicrobial susceptibility test that will aid in providing precise medical prescriptions to improve the health and well-being of patients.
MedFluid Founder and Head of Microfluidics R&D Bon Lee noted that, according to the World Health Organization (WHO), antimicrobial resistance was one of the ten threats to global health in 2019. It is happening around the world, and North America alone has more than 2 million cases and 23 thousand deaths.
MedFluid was selected as a bridge to MassChallenge Taiwan Top 14 Startups, selected for Taiwan Tech Arena (TTA)’s 2019 Prototyping Program, and was a top-15 team in the MOST FITI Innovation & Startups Program.